TABLE 3.
Effects of demographics, clinical factors, and transporter gene polymorphisms on rifampin AUC0-24 values
| Factor (no. of subjects) | Rifampin AUC0-24 |
P valuea | |
|---|---|---|---|
| Arithmetic mean (SD) | Geometric mean | ||
| Age, divided at median valuec | 0.73 | ||
| ≤33 yr (42) | 46.7 (22.7) | 41.1 | |
| >33 yr (44) | 45.3 (25.3) | 39.6 | |
| Sex | 0.44 | ||
| Male (70) | 43.7 (19.2) | 39.5 | |
| Female (16) | 56.2 (37.6) | 44.3 | |
| Groups | 0.59 | ||
| Healthy controls (16) | 44.0 (18.6) | 40.9 | |
| TB patients from Africa (37) | 43.2 (22.3) | 37.8 | |
| TB patients not from Africa (33) | 50.1 (27.8) | 43.1 | |
| Race | 0.21 | ||
| Black (46) | 42.1 (21.1) | 37.0 | |
| White (38) | 51.3 (26.8) | 45.2 | |
| Asian (2) | 34.3 | 34.1 | |
| HIV | 0.35 | ||
| Infected (3) | 34.3 (21.5) | 30.4 | |
| Not infected (82) | 46.6 (24.1) | 40.9 | |
| Diabetes mellitus | 0.82 | ||
| Present (8) | 48.4 (33.9) | 41.7 | |
| Not present (78) | 45.7 (23.0) | 40.2 | |
| Rifampin dosage in mg/kg divided at median valuec | 0.02 | ||
| <10.2 (44) | 39.5 (18.0) | 35.6 | |
| ≥10.2 (42) | 52.8 (27.5) | 46.0 | |
| Cavities on chest X-ray | 0.50b | ||
| None (16) | 44.2 (30.2) | 37.3 | |
| Cavities < 4 cm (32) | 46.0 (24.0) | 40.2 | |
| Cavities ≥ 4 cm (21) | 50.4 (22.8) | 45.0 | |
| Gene SNP | |||
| SLCO1B1 c.463C>A | <.001 | ||
| CC (71) | 49.4 (23.9) | 44.4 | |
| CA (15) | 29.9 (16.6) | 25.6 | |
| SLCO1B1 c.521T>C | 0.11 | ||
| TT (73) | 43.8 (22.6) | 38.5 | |
| TC (11) | 56.3 (30.5) | 50.2 | |
| CC (2) | 68.1 (15.6) | 67.2 | |
| SLCO1B1 c.1463G>C | 0.21 | ||
| GG (82) | 45.2 (23.6) | 39.7 | |
| GC (4) | 61.6 (28.7) | 55.7 | |
| SLCO1B1 c.388A>G | 0.29 | ||
| AA (11) | 50.1 (19.3) | 45.9 | |
| AG (32) | 49.1 (27.1) | 43.4 | |
| GG (43) | 42.7 (22.5) | 36.9 | |
| SLCO1B1 c.11187G>A | 0.39 | ||
| GG (78) | 44.8 (22.4) | 39.7 | |
| GA (8) | 57.4 (36.0) | 47.1 | |
| MDR1 c.3435C>T | 0.67 | ||
| CC (56) | 45.6 (25.0) | 39.5 | |
| CT (25) | 45.1 (21.4) | 40.7 | |
| TT (5) | 55.2 (27.2) | 49.2 | |
| SLCO1B3 c.334T>G | 0.99 | ||
| TT (19) | 44.5 (22.2) | 39.6 | |
| TG (42) | 46.4 (24.7) | 40.5 | |
| GG (25) | 46.4 (24.8) | 40.6 | |
a
P values obtained by ANOVA among all subjects for ln-transformed rifampin AUC0-24 values.
b
P values obtained by ANOVA among patients with tuberculosis for ln-transformed AUC0-24 values.
c
Low and high means shown for descriptive purposes. Pearson's correlation was nonsignificant for age (slope = 0.004, R-square = 0.01, P = 0.37) but significant for rifampin dosage (slope = 0.07, R-square = 0.06, P = 0.02).